Neurologie up2date, Table of Contents Neurologie up2date 2021; 04(03): 271-279DOI: 10.1055/a-1163-6617 Myopathien und Neuropathien Akute Polyradikuloneuritis: das Guillain-Barré-Syndrom Authors Martin K.R. Svačina Helmar C. Lehmann Recommend Article Abstract Buy Article(opens in new window) All articles of this category(opens in new window) Das Guillain-Barré-Syndrom (GBS) stellt die häufigste akute Polyradikuloneuritis dar. Neben rasch progredienten Paresen und Sensibilitätsstörungen können eine respiratorische Insuffizienz und eine Affektion des autonomen Nervensystems auftreten. Eine frühe Diagnosestellung und Therapie sind essenziell, um Komplikationen abzuwenden. Dieser Artikel beschreibt Ursachen und die klinische Versorgung bei einem GBS. Full Text References Literatur 1 Lehmann HC, Köhne A, Meyer zu Hörste G. et al. Incidence of Guillain-Barré syndrome in Germany. J Peripher Nerv Syst 2007; 12: 285 2 Dimachkie MM, Barohn RJ. Guillain-Barré syndrome and variants. Neurol Clin 2013; 491-510 3 van den Berg B, Walgaard C, Drenthen J. et al. Guillain-Barré syndrome: Pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol 2014; 10: 469-482 4 Lawn ND, Fletcher DD, Henderson RD. et al. Anticipating mechanical ventilation in Guillain-Barré syndrome. Arch Neurol 2001; 58: 893-898 5 Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet 2021; 397: 1214-1228 6 Hartung HP, Keller-Stanislawski B, Hughes RA. et al. Guillain-Barré-Syndrom nach Exposition mit Influenza. Nervenarzt 2012; 83: 714-730 7 Kajumba MM, Kolls BJ, Koltai DC. et al. COVID-19-Associated Guillain-Barre Syndrome: Atypical Para-infectious Profile, Symptom Overlap, and Increased Risk of Severe Neurological Complications. SN Compr Clin Med 2020; 8 Svačina MKR, Kohle F, Sprenger A. et al. Could symptom overlap of COVID-19 and Guillain–Barré syndrome mask an epidemiological association?. J Neurol 2021; 1-3 9 Derksen A, Ritter C, Athar P. et al. Sural sparing pattern discriminates Guillain-Barré syndrome from its mimics. Muscle Nerve 2014; 50: 780-784 10 Kaida K, Morita D, Kanzaki M. et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J Neuroimmunol 2007; 182: 212-218 11 Byun WM, Park WK, Park BH. et al. Guillain-Barre syndrome: MR imaging findings of the spine in eight patients. Radiology 1998; 208: 137-141 12 Razali SNO, Arumugam T, Yuki N. et al. Serial peripheral nerve ultrasound in Guillain-Barré syndrome. Clin Neurophysiol 2016; 127: 1652-1656 13 van Doorn PA, Kuitwaard K, Walgaard C. et al. IVIG treatment and prognosis in guillain-barré syndrome. J Clin Immunol 2010; 30 (Suppl. 01) S74-78 14 Hughes RA, Brassington R, Gunn AA. et al. Corticosteroids for Guillain-Barré syndrome. Cochrane Database Syst Rev 2016; 10: CD001446 15 van Doorn PA, Ruts L, Jacobs BC. Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 2008; 7: 939-950 16 Lehmann HC, Jangouk P, Kierysch EK. et al. Autoantibody-mediated dysfunction of sympathetic neurons in Guillain-Barré syndrome. Arch Neurol 2010; 67: 203-210 17 Ho TW, Willison HJ, Nachamkin I. et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barre syndrome. Ann Neurol 1999; 45: 168-173 18 Toscano G, Palmerini F, Ravaglia S. et al. Guillain-Barré Syndrome Associated with SARS-CoV-2. N Engl J Med 2020; 382: 2574-2576 19 Lehmann HC, Schoser B, Wunderlich G. et al. Neuromuscular complications of SARS-CoV-2 infections – Part 1: peripheral nerves. Nervenarzt 2021; 1-6 20 Burina A, Sinanović O, Smajlović D. et al. Bilateral oculomotor nerve palsy in Guillain-Barre syndrome. Med Arh 2008; 62: 119-120 21 Wakerley BR, Yuki N. Mimics and chameleons in guillain-barré and miller fisher syndromes. Pract Neurol 2015; 15: 90-99 22 Kerasnoudis A, Pitarokoili K, Behrendt V. et al. Nerve ultrasound score in distinguishing chronic inflammatory demyelinating polyneuropathy from Guillain-Barré syndrome. J Neurol Sci 2013; 333 (Suppl. 01) E442-E443 23 Berciano J, Orizaola P, Gallardo E. et al. Very early Guillain-Barré syndrome: A clinical-electrophysiological and ultrasonographic study. Clin Neurophysiol Pract 2020; 5: 1-9 24 West TW. Transverse myelitis – a review of the presentation, diagnosis, and initial management. Discov Med 2013; 16: 167-177 25 Yen LM, Thwaites CL. Tetanus. Lancet 2019; 393: 1657-1668 26 Hemachudha T, Ugolini G, Wacharapluesadee S. et al. Human rabies: Neuropathogenesis, diagnosis, and management. Lancet Neurol 2013; 12: 498-513 27 Koedel U, Fingerle V, Pfister HW. Lyme neuroborreliosis – Epidemiology, diagnosis and management. Nat Rev Neurol 2015; 11: 446-456 28 Tankisi H, de Carvalho M, ZʼGraggen WJ. Critical Illness Neuropathy. J Clin Neurophysiol 2020; 37: 205-207 29 Gilhus NE. Myasthenia Gravis. N Engl J Med 2016; 375: 2570-2581 30 Suresh E, Wimalaratna S. Proximal myopathy: Diagnostic approach and initial management. Postgrad Med J 2013; 89: 470-477 31 Saxena A, Godena E, Maggio J. et al. Towards an outpatient model of care for motor functional neurological disorders: A neuropsychiatric perspective. Neuropsychiatr Dis Treat 2020; 16: 2119-2134 32 Svačina MKR, Röth P, Bobylev I. et al. Changes of Serum IgG Dimer Levels after Treatment with IVIg in Guillain-Barré Syndrome. J Neuroimmune Pharmacol 2019; 14: 642-648 33 Walgaard C, Jacobs BC, Lingsma HF. et al. Second intravenous immunoglobulin dose in patients with Guillain-Barré syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial. Lancet Neurol 2021; 20: 275-283
